Celldex Therapeutics (CLDX) stock price, revenue, and financials

Celldex Therapeutics market cap is $36 m, and annual revenue was $9.54 m in FY 2018

$36 M

CLDX Mkt cap, 16-Oct-2019

$715 K

Celldex Therapeutics Revenue Q2, 2019
Celldex Therapeutics Net income (Q2, 2019)-11.8 M
Celldex Therapeutics EBIT (Q2, 2019)-12.3 M
Celldex Therapeutics Cash, 30-Jun-201919.7 M
Celldex Therapeutics EV18.8 M

Celldex Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

169.4m28.0m72.1m42.5m40.3m24.3m

Accounts Receivable

489.0k427.0k97.0k1.8m

Current Assets

305.2m205.0m294.9m195.6m144.8m99.1m

PP&E

10.0m10.5m11.5m13.2m10.4m6.1m

Goodwill

9.0m9.0m9.0m91.0m91.0m

Total Assets

347.1m248.0m337.6m383.4m315.6m155.8m

Accounts Payable

2.2m2.6m1.5m1.7m1.7m1.1m

Current Liabilities

20.4m24.5m30.2m35.2m27.7m12.6m

Total Liabilities

27.3m47.5m117.9m79.3m31.7m

Additional Paid-in Capital

662.7m672.7m878.7m982.3m1.0b1.1b

Retained Earnings

(345.7m)(463.8m)(591.0m)(719.5m)(812.5m)(962.4m)

Total Equity

319.8m211.7m290.1m265.4m236.4m124.1m

Financial Leverage

1.1 x1.2 x1.2 x1.4 x1.3 x1.3 x

Celldex Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(81.5m)(118.1m)(127.2m)(128.5m)(93.0m)(151.2m)

Depreciation and Amortization

1.9m2.4m3.0m3.1m4.4m3.6m

Accounts Payable

7.2m1.5m4.9m(5.0m)(8.7m)(13.1m)

Cash From Operating Activities

(67.7m)(101.5m)(98.9m)(113.0m)(99.9m)(75.2m)

Purchases of PP&E

(4.2m)(1.9m)(4.9m)(2.8m)(1.8m)(813.0k)

Cash From Investing Activities

(77.4m)(41.0m)(50.2m)68.9m46.5m29.8m

Cash From Financing Activities

289.6m1.2m193.2m14.5m51.3m29.4m

Interest Paid

1.2m1.2m1.2m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019

Net Income

(59.5m)(29.9m)(58.2m)(86.3m)(32.4m)(32.0m)(34.7m)(32.0m)(29.6m)(34.3m)(62.8m)(89.2m)(118.1m)(134.5m)(17.2m)(29.0m)

Depreciation and Amortization

1.4m579.0k1.2m1.8m1.4m2.4m3.4m1.0m2.0m1.4m2.5m

Accounts Payable

3.0m(1.7m)(1.0m)(740.0k)3.1m2.0m1.2m2.6m706.0k1.0m(8.3m)(6.8m)(10.9m)(5.9m)(5.9m)(1.5m)(1.6m)

Cash From Operating Activities

(52.7m)(31.9m)(52.7m)(79.3m)(35.3m)(56.0m)(80.4m)(28.0m)(45.4m)(13.2m)(24.3m)

Purchases of PP&E

(1.9m)(195.0k)(1.1m)(1.8m)(374.0k)(1.3m)(1.6m)(259.0k)(591.0k)(186.0k)(484.0k)

Cash From Investing Activities

(63.6m)(81.3m)(76.7m)(58.7m)22.4m58.2m59.9m15.5m28.7m16.3m8.3m

Cash From Financing Activities

106.0m702.0k856.0k1.2m12.9m21.6m32.8m12.1m20.3m4.2m11.4m

Celldex Therapeutics Ratios

USDY, 2019

EV/EBIT

-1.5 x

EV/CFO

-0.8 x

Financial Leverage

1.3 x

Celldex Therapeutics Operating Metrics

FY, 2016

Patents Issued

300

Celldex Therapeutics Employee Rating

3.618 votes
Culture & Values
3.8
Work/Life Balance
4.2
Senior Management
3.4
Salary & Benefits
3.6
Career Opportunities
2.9
Source